{
    "clinical_study": {
        "@rank": "85944", 
        "arm_group": {
            "arm_group_label": "Alemtuzumab", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver\n      cancer-killing substances to them without harming normal cells. Compassionate use refers to\n      providing a drug to a patient on humanitarian grounds before the drug has received official\n      approval.\n\n      PURPOSE: Compassionate use of Campath-1H in treating patients who have refractory\n      prolymphocytic leukemia or chronic lymphocytic leukemia."
        }, 
        "brief_title": "Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia", 
        "completion_date": {
            "#text": "May 2002", 
            "@type": "Actual"
        }, 
        "condition": "Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Leukemia, Prolymphocytic"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Expand access to Campath-1H for patients with refractory prolymphocytic\n      leukemia or chronic lymphocytic leukemia.\n\n      OUTLINE: Patients receive Campath-1H IV over 2 hours on days 1, 3, and 5. Treatment repeats\n      weekly for 4-12 weeks in the absence of disease progression or unacceptable toxicity.\n\n      PROJECTED ACCRUAL: Not specified"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Confirmed prolymphocytic leukemia (PLL) or chronic lymphocytic\n        leukemia (CLL) PLL that has failed at least 1 prior regimen CLL that has failed prior\n        fludarabine, defined as: No response Disease progression while receiving therapy OR\n        Relapse within 6 months of completion of last dose\n\n        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-2 Life expectancy: Not\n        specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2 times upper\n        limit of normal (ULN) (unless secondary to direct liver infiltration with CLL) Renal:\n        Creatinine no greater than 2 times ULN Other: HIV negative No active infection No other\n        severe concurrent disease No mental disorders No prior allergic reaction to rat or\n        mouse-derived CDR-grafted humanized monoclonal antibodies Not pregnant or nursing Negative\n        pregnancy test Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n        Characteristics At least 3 weeks since prior chemotherapy No concurrent cytotoxic therapy\n        Endocrine therapy: Not specified Radiotherapy: At least 3 weeks since prior radiotherapy\n        Surgery: Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "2", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 11, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00021151", 
            "org_study_id": "ILEX1999", 
            "secondary_id": [
                "CWRU-ILEX-1999", 
                "ILEX-CAM511-A1", 
                "NCI-G01-1977"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Alemtuzumab", 
            "intervention_name": "alemtuzumab", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Alemtuzumab", 
                "Campath 1G"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "refractory chronic lymphocytic leukemia", 
            "prolymphocytic leukemia"
        ], 
        "lastchanged_date": "January 7, 2014", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/CWRU-ILEX-1999"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Cleveland", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "44106-5065"
                }, 
                "name": "Ireland Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "CAMPATH-1H Compassionate Treatment In Patients With PLL Who Have Failed At Least One Prior Regimen And CLL Patients Who Have Failed Fludarabine Therapy", 
        "overall_official": {
            "affiliation": "University Hospitals Seidman Cancer Center", 
            "last_name": "Bernard J. Silver, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2001", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00021151"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "11986207", 
            "citation": "Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002 May 15;99(10):3554-61."
        }, 
        "source": "Case Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Cancer Institute (NCI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Genzyme, a Sanofi Company", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Case Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2000", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }, 
    "geocoordinates": {
        "Ireland Cancer Center": "41.499 -81.695"
    }
}